
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
The American Academy of Pediatrics in 2014 revised its recommendation for timing of the HPV vaccination with a unified dosing schedule.
The American Academy of Pediatrics in its
The recommendation of the AAP is that the second dose of HPV vaccine be given:






